These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37169178)

  • 21. A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease.
    Zhang Q; Tao H; Lin Y; Hu Y; An H; Zhang D; Feng S; Hu H; Wang R; Li X; Zhang J
    Biomaterials; 2016 Oct; 105():206-221. PubMed ID: 27525680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems.
    Hadji H; Bouchemal K
    Adv Drug Deliv Rev; 2022 Feb; 181():114101. PubMed ID: 34999122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug delivery strategies in the therapy of inflammatory bowel disease.
    Lautenschläger C; Schmidt C; Fischer D; Stallmach A
    Adv Drug Deliv Rev; 2014 May; 71():58-76. PubMed ID: 24157534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SHARP hydrogel for the treatment of inflammatory bowel disease.
    Poláková L; Raus V; Cuchalová L; Poręba R; Hrubý M; Kučka J; Větvička D; Trhlíková O; Sedláková Z
    Int J Pharm; 2022 Feb; 613():121392. PubMed ID: 34933083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation-targeting polyamine nanomedicines for the treatment of ulcerative colitis.
    Nishiguchi A; Taguchi T
    J Mater Chem B; 2023 May; 11(18):4005-4013. PubMed ID: 37039159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ROS Scavenging and inflammation-directed polydopamine nanoparticles regulate gut immunity and flora therapy in inflammatory bowel disease.
    Bao M; Wang K; Li J; Li Y; Zhu H; Lu M; Zhang Y; Fan Q; Han L; Wang K; Wang D; Gao Y; Peng B; Ming Z; Liu W
    Acta Biomater; 2023 Apr; 161():250-264. PubMed ID: 36863680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The application of natural product-delivering micro/nano systems in the treatment of inflammatory bowel disease.
    Zhou Y; Feng X; Xu H; Guo J; Yang C; Kong L; Zhang Z
    J Mater Chem B; 2023 Jan; 11(2):244-260. PubMed ID: 36512384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease.
    Zhang S; Ermann J; Succi MD; Zhou A; Hamilton MJ; Cao B; Korzenik JR; Glickman JN; Vemula PK; Glimcher LH; Traverso G; Langer R; Karp JM
    Sci Transl Med; 2015 Aug; 7(300):300ra128. PubMed ID: 26268315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation-responsive delivery systems for the treatment of chronic inflammatory diseases.
    Deng Z; Liu S
    Drug Deliv Transl Res; 2021 Aug; 11(4):1475-1497. PubMed ID: 33860447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases.
    Sun Q; Luan L; Arif M; Li J; Dong QJ; Gao Y; Chi Z; Liu CG
    Carbohydr Polym; 2018 Jun; 189():352-359. PubMed ID: 29580419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitochondria-targeted supramolecular coordination container encapsulated with exogenous itaconate for synergistic therapy of joint inflammation.
    Chen X; Li C; Cao X; Jia X; Chen X; Wang Z; Xu W; Dai F; Zhang S
    Theranostics; 2022; 12(7):3251-3272. PubMed ID: 35547753
    [No Abstract]   [Full Text] [Related]  

  • 32. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa.
    Sharma S; Sinha VR
    J Control Release; 2018 Feb; 272():97-106. PubMed ID: 29317245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ROS-Sensitive Polymer Micelles for Selective Degradation in Primary Human Monocytes from Patients with Active IBD.
    Gardey E; Sobotta FH; Quickert S; Bruns T; Brendel JC; Stallmach A
    Macromol Biosci; 2022 Apr; 22(4):e2100482. PubMed ID: 35068059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in Pharmaceutical Strategies Enhancing the Efficiencies of Oral Colon-Targeted Delivery Systems in Inflammatory Bowel Disease.
    Guo Y; Zong S; Pu Y; Xu B; Zhang T; Wang B
    Molecules; 2018 Jul; 23(7):. PubMed ID: 29973488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
    Kesisoglou F; Zimmermann EM
    Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing polymer-derived drug delivery systems for combating inflammatory bowel disease.
    Pu Y; Fan X; Zhang Z; Guo Z; Pan Q; Gao W; Luo K; He B
    J Control Release; 2023 Feb; 354():1-18. PubMed ID: 36566845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease.
    Gowd V; Kanika ; Jori C; Chaudhary AA; Rudayni HA; Rashid S; Khan R
    J Nutr Biochem; 2022 Nov; 109():109101. PubMed ID: 35777588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy.
    Zhang C; Wang H; Yang X; Fu Z; Ji X; Shi Y; Zhong J; Hu W; Ye Y; Wang Z; Ni D
    Sci Adv; 2022 Sep; 8(37):eabp9882. PubMed ID: 36112678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging Nanotechnologies and Microbiome Engineering for the Treatment of Inflammatory Bowel Disease.
    Abed OA; Attlassy Y; Xu J; Han K; Moon JJ
    Mol Pharm; 2022 Dec; 19(12):4393-4410. PubMed ID: 35878420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease.
    Zhang Y; Thanou M; Vllasaliu D
    Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.